By Anne Urda ( February 4, 2008, 12:00 AM EST) -- The race to be the world's anti-influenza drug leader continues to heat up, with Biota's Relenza receiving a leg up in light of a new study that is questioning the effectiveness of Roche Holdings AG's blockbuster Tamiflu....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.